Vivek Ramaswamy (Jeff Rumans/JPM 2020)
November 25, 2020 07:28 AM EST
R&D

Urovan­t's lead drug dis­ap­points in mid-stage study as first big FDA de­ci­sion looms

Amber Tong

Just as Urovant gets ready for its first big FDA de­ci­sion on vibegron, the drug has flopped in what would’ve been a fol­low-on in­di­ca­tion. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Can Bill An­der­son save Bay­er?

Drug pol­i­cy vet­er­an at CMS to de­part on Fri­day

Verve is lat­est gene edit­ing com­pa­ny to suf­fer set­back, as Ver­tex walks away from pact

Phar­ma-backed Mis­sion Ther­a­peu­tics stops pre­clin­i­cal op­er­a­tions, fo­cus­es on two clin­i­cal as­sets

CDC is in­ves­ti­gat­ing five hos­pi­tal­iza­tions af­ter use of Val­ne­va’s chikun­gun­ya vac­cine

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times